The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | Improving responses to immunotherapy in NSCLC
Victor Moreno, MD, PhD, of University Hospital Fundación Jiménez Díaz, Madrid, Spain, explores avenues for overcoming resistance to immunotherapy in cancer patients, and highlights a major advancement in precision oncology at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Dr Moreno discusses the outcomes from a recent clinical trial (NCT02383212), involving the combination of cemiplimab and radiotherapy in non-small cell lung cancer (NSCLC) patients, to demonstrate the ongoing efforts to limit resistance to immunotherapy. Dr Moreno also draws attention to a fascinating clinical trial investigating larotrectinib – a targeted therapy for patients with TRK fusions.
